CENTRE FOR RESPIRATORY DISEASES RESEARCH (CRDR) NAIROBI
The Centre for Respiratory Diseases Research (CRDR) is a centre of the Kenya Medical Research Institute (KEMRI).
The centre was started the early fifties when Tuberculosis Research was carried out under the auspices of East African Community: Kenya, Uganda and Tanganyika (Tanzania) all under British rule.
The present CRDR premises were constructed in the early seventies with its extension put up in 1980.
The Centre comprises 50 members of staff. 26 Research/scientific staff and 24 Administrative/support staff.
To conduct research on respiratory diseases of public health importance in order to improve the health of Kenyans.
To be a leading Centre of excellence in Respiratory Diseases Research nationally, towards the improvement of humanity health
- TB epidemiology, case finding and holding, immunization, pharmacotherapy of TB and pharmacoepidemiology of drug resistance TB in HIV infection.
- Non-TB respiratory diseases: high priority pathologies eg. Bronchial asthma, industrial respiratory implications and acute respiratory infections.
- Lung function.
- Immunology of the TB and allergic conditions.
- Environmental and occupational health.
- Good Corporate Governance
- Creativity and Innovation
- Sanctity of life
Ongoing Projects (Jan 2020 - July 2020 )
- SERU A Randomized Double Blind, Parallel-Group, Multicenter, Phase III Study to Evaluate the Effect of Ticagrelor versus Placebo in Reducing the Rate of Vaso-occlusive Crises in pediatric patients with Sickle Cell Disease
- An Open Label Extension Study of GBT440 Administered Orally to Patients with Sickle Cell Disease Who Have Participated in GBT440 Clinical Trials
- SERU No.3438 An Open Label Extension Study of GBT 440 Administered Orally to patients with Sickle Cell Disease Who Have Participated in GBT 440 Clinical Trial
- SERU No. 3720 A Randomized Double Blind, Parallel-Group, Multicenter, Phase III Study to Evaluate the Effect of Ticagrelor versus Placebo in Reducing the Rate of Vaso-occlusive Crises in pediatric patients with Sickle Cell Disease (HESTIA 3)
- SERU No. 3630 – A Randomized, Open label, Parallel-group, Single Dose Regimen, Phase 2a Study to Investigate the Clinical and Parasiticidal Activity and the Pharmacokinetics of 3 dose levels of Artefenomel (OZ439) given in combination with Ferroquine (FQ) and FQ in African Patients with Uncomplicated Plasmodium falciparum Malaria
- SERU 3681 – “Prevalence of pulmonary tuberculosis and HIV among long distance truck drivers and commercial sex workers in Mlolongo, Machakos County.”
- SERU 3631 – Pulmonary and latent Tuberculosis in public transportation in Nairobi County, Kenya.
- SERU 3662- A Phase 3, Randomized, Double-Blind, Placebo Controlled Study of Voxelotor (GBT440) in Pediatric Participants with Sickle Cell Disease and an Open-label Study in Infants with Sickle Cell Disease. (HOPE Kids2).
- SERU 3988 – Epidemiologic,Transmission, Immunogenetic and Diagnostic studies of Mycobacterium Tuberculosis
- SERU 3959 – Safety and Immunogenicity Study of Full Schedule (3-Dose SHAN6™) or SHAN6™- SHAN 5®- SHAN6™ Versus the Licensed Vaccine SHAN 5® With bOPV and IPV When Administered Per National Immunization Schedule in Healthy Kenyan Infants (Shan 6)
- SERU 3977 -A multicentre, phase III, double-blind, randomized, active-controlled study to evaluate the efficacy and safety of VPM1002 in comparison with BCG in prevention of Mycobacterium tuberculosis infection in new-born infants
- SERU 2519 – The burden of Obstructive Lund Diseases in Nairobi and its environs
- SERU 3944 – Non-communicable lung disease in Kenya: from burden and early life determinants to participatory inter-disciplinary solutions; The TUPUMUE Study
- SERU 3761 – A cross-sectional study, of the characteristics of adults with chronic respiratory symptoms attending outpatient departments at Mbagathi Hospital in Nairobi, Kenya : A Multi- Center study
- SERU – 3717 – Chronic respiratory symptoms in adults and children in Kenya: how do health systems respond and what are the opportunities for health system strengthening.
- SERU 3840 – The Utility of Clinician-Performed Cardiopulmonary Ultrasound Assessment of the Acutely Breathless Patient: Breathlessness Early Detection with Ultrasound trial (BED-US Trial)
- SERU 3887 – Role of IL-17 Cytokine networks in TB relapse due to HIV7.
- SERU 3674: A Comparative Study on the Quality of Life of Leprosy Patients, their Household Contacts and the Public Health Implications of Zoonotic
- SERU 3234 – Geomatic Mapping Of Indoor Fungi And Their Associated Respiratory Health Effects In Residential Environments, In Nairobi and Busia Urban Counties, Kenya.clinical sources in Nairobi
- SERU 3742 Genotypic and phenotypic characterization of Fusarium species from soils in Mycotoxic “hot zones” in Eastern County-Kenya
KEMRI - VCT
CRDR Clinical Trial Annex
Non-communicable Disease (NCDs)
Dr. Videlis Nduba
Deputy Director Centre for Respiratory Disease Research
Dr. Videlis Nduba has worked at the Institute for over 13 years with his work focusing on TB Research including developing tuberculosis epidemiological capacity to conduct phase II and III TB vaccine trials in adolescents and infants, diagnostics for infant TB, and epidemiology of TB in adolescents. He was a principal investor of a double-blind, randomised, placebo-controlled, dose-finding trial of the novel tuberculosis vaccine AERAS-402) in infants, of which Kenya was one of four countries participating in this trial.